The hepatitis C cure rate among patients in the Veterans Affairs health system increased 21-fold from 1999 to 2015 because of the use of direct-acting antiviral drugs, according to a study in Alimentary Pharmacology & Therapeutics. "Further increases in funding and cost reductions of DAAs in 2016 suggest that the VA could cure the majority of HCV-infected Veterans in VA care within the next few years," the study authors wrote.
White Paper: HCLL Delivers Safe and Reliable Integration with Epic
HCLL™ Transfusion blood bank information system (BBIS) and Epic® support the flow of orders, product preparation, issue and release, PPID at the bedside, and transfusion, as well as provide complete and automatic documentation. Whether your BBIS or LIS is stand-alone or all-in-one, integration among systems is the best way to enable real-time care that minimizes errors and keeps patients safe. Download now.
The World Health Organization has set a goal of reducing malaria cases by 40% by 2020, but the number of cases has risen in Burundi and Rwanda. The number of malaria-related deaths in Burundi is 3,700 since last year.
TiGenix, a Belgian cell therapeutics company, said a Phase I/II trial found that patients who received 35 million-cell intracoronary infusions of AlloCSC-01, an allogenic stem cell therapy, in the week after an acute myocardial infarction had no major cardiac adverse events or deaths in the year after treatment. "This is the first trial in which it has been demonstrated that allogeneic cardiac stem cells can be transplanted safely through the coronary tree, and in the worst possible setting represented by patients with an acute heart attack with left ventricular dysfunction," said researcher Fernandez-Aviles of the Hospital General Universitario Gregorio Maranon in Madrid.
Neon Therapeutics agreed to collaborate with Vedantra Pharmaceuticals to research cancer vaccines that target neoantigens to enable the body to produce more immune cells to fight cancer. The collaboration will use Neon's neoantigen vaccine research capabilities with lymph node-targeting amphiphile technology from Vedantra.
The FDA placed a partial hold on the development of Karyopharm Therapeutics' leukemia drug candidate selinexor, or KPT-330, because of incomplete data in the investigator's brochure for the drug, including a list of serious adverse events that was not complete. An amended version has been submitted to the FDA, the company said.
Annual Meeting Call for Abstracts Don’t Wait! Now is your chance to submit an abstract for the 2017 AABB Annual Meeting. Share your research with more than 5,000 attendees from around the world, publish your work in TRANSFUSION Journal and gain recognition in your field! Submit your abstract by April 27, 2017.
AABB encourages members to consider a donation in support of the National Blood Foundation's Early Career Scientific Research Grants Program. The NBF is currently evaluating 2017 grant applications and identifying applicants with the most promising and novel approaches in transfusion medicine, cellular therapies and patient blood management. Donations help fledgling scientists embark on a career in research and promote pioneering methods that could provide insight to advance the field, improve treatments and, ultimately, save lives.